Pharmaceutical industry – Page 50
-
Business
Perrigo bags Elan and its bargain Irish tax rates
$8.6bn deal ends Elan’s takeover battle with Royalty Pharma
-
Business
Thousands face job cuts after Valeant's Bausch buyout
Valeant plans to shed 10-15% of its workforce to save $800 million
-
BusinessChina corruption investigation broadens
GSK scandal is the trigger to clean up Chinese drug market
-
BusinessLilly freezes pay as patent cliff looms
Drugmaker targets $400 million savings as two key patents near expiry
-
Business
GSK under investigation over corruption in China
Police claim executives engaged in bribery and tax-related crimes
-
Business
Evotec moves business back to UK
Pharma company closes operations in India, citing distance from customers
-
Business
Biosimilar drugs step up complexity
First generic monoclonal antibodies recommended for approval in Europe
-
OpinionTarget acquired
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be
-
Business
Aspen in $1 billion deal with Merck & Co
South African generics manufacturer to buy 11 drug brands and an API business from the US drugmaker
-
Business
Data-sharing partnership for drug discovery
Collaborative project aims to assist medicinal chemistry efforts
-
Business
Ups and downs for erectile dysfunction drugs
First new drug in a decade approved in Europe as Viagra patent expires
-
Business
NHS to offer breast cancer prevention drugs
Five-year course of tamoxifen or raloxifene recommended for high risk women
-
CareersGoing with the flow chemistry
Elizabeth Farrant climbed to the top in big pharma, but now she’s working at a smaller scale, as Sarah Houlton finds out
-
BusinessAstraZeneca announces new UK hub
Restructuring will see all AstraZeneca R&D at new location close to University of Cambridge research
-
Business
Companies urged to publish hidden clinical trial data
Researchers could acquire data and publish themselves if firms refuse
-
Business
GSK fires Chinese R&D head in data investigation
Company is retracting a 2010 study in which data were ‘misrepresented’
-
Business
Pfizer and Takeda win $2.15bn in patent payout
Teva and Sun fined for selling generics before patent expiry